Samuel A. Wickline, M.D.
Date: February 8, 2008
Personal Information
Sex: Male
Date of Birth: October 23, 1952
Place: Huntington, West Virginia
Marital Status: Married to Karen M. Wickline, M.D., Associate Professor of Pediatrics
and Neonatology, Children’s Hospital, Washington University School of Medicine
Citizenship
USA
Current Address
Office: Cardiovascular Division; Washington University School of Medicine; 660 South
Euclid Avenue; St. Louis, MO 63110; Telephone: 314-454-8811;
Email: saw@howdy.wustl.edu
Home: 11211 Pointe Court; St. Louis, MO 63127; Telephone: 314-842-2300
Present Positions
Professor of Medicine, Washington University School of Medicine
Professor of Physics, Washington University
Professor of Biomedical Engineering, Washington University
Professor of Cell Biology and Physiology, Washington University
Director, Washington University Consortium for Translational Research in Advanced Imaging
and Nanomedicine (C-TRAIN)
Director, Siteman Center For Cancer Nanotechnology Excellence
Executive Faculty, Institute of Biological and Medical Engineering
Co-Director of Cardiovascular Engineering Graduate Training Program, Biomedical
Engineering Department, Washington University
Education
Undergraduate:
Graduate:
Pomona College; Claremont, California (1970-74)
BA: Philosophy
University of Hawaii School of Medicine;
Honolulu, Hawaii (1976-1980)
Academic Positions/Employment
1974-1976: Research Associate, Cardiovascular Research Laboratory,
Queens Hospital and John A. Burns School of Medicine;
Honolulu, Hawaii
1
1980-83:
Internship and Residency in Internal Medicine: Barnes Hospital;
Washington University School of Medicine; St. Louis, MO
1983-87:
Clinical and Research Fellowships in Cardiology:
Washington University School of Medicine; Barnes
Hospital; St. Louis, MO (Research Fellow 1983-85)
1987:
Assistant Professor of Medicine
Washington University School of Medicine
Barnes Hospital; St. Louis, MO
1988:
Clinician-Scientist of the American Heart Association
1990:
Assistant Professor of Physics
Washington University, Department of Physics; St. Louis, MO
1992:
Attending Cardiologist and Director of Echocardiography
The Jewish Hospital at Washington University; St. Louis, MO
1993:
Established Investigator of the American Heart Association
1993:
Associate Professor of Medicine
Washington University School of Medicine
1993-97:
Chief of Cardiology, Jewish Hospital
Washington University School of Medicine
1994:
Associate Professor of Physics
Washington University, Department of Physics; St. Louis, MO
1996:
Co-Director of Cardiovascular Division, Washington University School of
Medicine and Barnes-Jewish Hospital
1996:
Co-Director of Washington University Cardiovascular Engineering Program and
Member of Executive Council, Institute of Biological and Medical Engineering,
Washington University, School of Engineering and Applied Sciences
1997:
Professor of Medicine
Washington University School of Medicine
1997:
Professor of Physics and of Biomedical Engineering
Washington University School of Medicine
2
2003:
Professor of Cell Biology and Physiology
Division of Biology and Biomedical Sciences
Washington University School of Medicine
University and Hospital Appointments and Committees
Director, Consortium for Translational Research in Advanced Imaging and Nanomedicine
(C-TRAIN)
Director, Siteman Center For Cancer Nanotechnology Excellence
Co-Director, Cardiovascular Engineering Graduate Program, Biomedical Engineering
Member, Executive Board of the Institute of Biological and Medical Engineering
Member, Washington University Center for Materials Innovation
Member, Program in Computational Biology, Division of Biology and Biological Sciences
Mentor, Program Committee on Imaging Sciences
Medical License and Board Certification
Medical License (R7B93), State of Missouri, 1983
Diplomate of the National Board of Medicine I, II, and III
Diplomate of the American Board of Internal Medicine, 1984
Diplomate of the American Board of Internal Medicine, Cardiology, 1988
Honors and Awards
1)
B.A. degree: Cum Laude; Pomona College
2)
Lange Award for Outstanding Student sophomore, junior, and senior years; John
A. Burns School of Medicine; Honolulu, Hawaii
3)
First place awardee: University of Hawaii Biomedical Science Symposium (1977)
for presentation of "Vectorcardiographic Infarct Sizing in Baboons"
4)
Alpha Omega Alpha, 1979
5)
Knowlton "Incentive For Excellence" Award, Internal Medicine Program,
Washington University School of Medicine, 1986
6)
Clinician-Scientist Award, American Heart Association, 1988-93
7)
Established Investigator Award, American Heart Association, 1993-1998
8)
Member, American Society of Clinical Investigation (Elected May 1995)
9)
Elected to Board of Directors, Society for Cardiovascular Magnetic
Resonance, 2000-2004
10)
Elected Councilor to Society of Molecular Imaging (2004-2007)
11)
Fellow of the American College of Cardiology
12)
Fellow of the American Heart Association
13)
2006 Reneman Laureate, University of Maastricht and Cardiovascular Research
Institute of Maastricht
Review/Editorial/Other Responsibilities
Editorial Board: Journal of the Society of Cardiac Magnetic Resonance, Journal of
Molecular Imaging, Current Cardiology Reviews
3
Reviewer for Journal of Clinical Investigation, Circulation, American Heart Journal, Coronary
Artery Disease, Circulation Research, Atherosclerosis, Arteriosclerosis and Thrombosis,
Hypertension, Journal of the American College of Cardiology, Ultrasound in Medicine and
Biology, IEEE Ultrasonics Ferroelectrics and Frequency Control, Journal of Thoracic and
Cardiovascular Surgery
Standing Member NIH Study Section in Diagnostic Radiology, 1996-2000
Annual Scientific Program Chair Society Cardiovascular Magnetic Resonance, 1998 and 1999
Member NHLBI Special Emphasis Panel on Heart and Vascular Diseases, 1997
Member of NHLBI "SPARK-2" Working Group, Claude Lenfant, NHLBI, Director, January 2003
Member NHLBI Nanotechnology Working Group, February 2003
Member NIH Roadmap Working Group: "High-Risk Research", June 2003
NCI Nanotechnology Working Group, January 2004
Member Scientific Program Committee International Society of Magnetic Resonance in Medicine
(ISMRM), 2004-2006
Scientific Advisory Board Member, Rice University Center for Biological Engineering
Nanotechnology, 2004-2006
NHLBI Strategic Planning Program, Executive Committee member (Betsy Nabel, Chair), 2006-2007
NIH Roadmap Planning Program Member (Elias Zerhouni, Chair), 2006-2007
Professional Societies and Organizations
Fellow, American College of Cardiology
Fellow, American Heart Association
American Federation for Clinical Research
American Heart Association, Councils on Radiology and Clinical Cardiology
American Institute of Ultrasound in Medicine
Acoustical Society of America
IEEE Society of Ultrasonics, Ferroelectrics, and Frequency Control
Founding Member, Society of Cardiovascular Magnetic Resonance Imaging
Society of Molecular Imaging
Selected Major Invited National/International Academic Lectures since 1995
1995 Plenary Session Co-Chairman and Invited Speaker at June 1995 International Acoustical
Society, (Trondheim, Norway)
1995 Plenary Session Invited Speaker for Acoustical Society of America 126th International
Meeting, (St. Louis, MO)
1995 Borun Visiting Professor, UCLA, November 11, 1995 (Los Angeles, CA)
1996 Invited International Speaker at Japanese Circulation Society Meeting (60th Annual
Meeting), “Site Targeted Ultrasound Contrast”, March 21, 1996 (Osaka, Japan)
1996 Co-Organizer Cardiovascular Science and Technology Conference (NIH Affiliated),
Session Chairman and Invited Speaker, May 2-3, 1996 (Washington, D.C.)
1996 Plenary Session Invited Speaker for 1996 QNDE (Quantitative Nondestructive Evaluation)
National Meeting, August 1996, Portland, Maine
1996 Plenary Session Speaker, Co-Organizer, and Co-Chairman of First NIH “Working
Group” Conference on Cardiovascular MRI, September 1996 (Bethesda, MD)
4
1996
1997
1997
1997
1997
1997
1998
1999
1999
1999
1999
1999
1999
2000
2000
2000
2000
2000
2000
Plenary Session Invited Speaker for Japanese Society for Magnetic Resonance in Medicine,
September 11-13, 1996 (Tokyo, Japan)
Invited Speaker to “Interdisciplinary Workshop in New Developments in Noninvasive
Cardiac Imaging”, sponsored by European Society of Cardiology, May 1997 (Alpbach,
Austria)
Invited Speaker to American Society for Artificial Internal Organs, “Imaging Infections in
Implanted Devices”, May 1997 (Atlanta, GA)
Plenary Session Speaker for QNDE (Quantitative Nondestructive Evaluation) International
Meeting, “ Cardiovascular MRI”, July 29, 1997 (San Diego, CA)
Invited Speaker to NHLBI Workshop on “Treatment and Diagnosis of Cardiac Maladaptive
Remodeling”, September 15-16, 1997, NIH (Bethesda, MD)
Co-Chairman of NHLBI Special Emphasis Panel on “Thrombosis and Infection in
Implanted Medical Devices”, October 1997, Natcher Auditorium, NIH (Bethesda, MD)
Invited Panelist to NIH Symposium “Bioengineering: Building the Future of Biology and
Medicine”, February 27-28, 1998 (Bethesda, MD)
Program Chairman for Society for Cardiovascular MR Annual Scientific Session, January 1999
(Atlanta, GA)
Invited Speaker to Society for Cardiovascular Magnetic Resonance Symposium, The Role
of MRI in Cardiology, on “Integrating CMR in Cardiology”, March 6, 1999 (New Orleans, LA)
Invited Speaker to American College of Cardiology 48th Annual Scientific Session, New
Developments in Contrast Echo, on “Targeted Agents for Enhanced Therapy”, March 9, 1999
(New Orleans, LA)
Invited Speaker to “Interdisciplinary Workshop in New Developments in Noninvasive Cardiac
Imaging”, sponsored by European Society of Cardiology, May 1999 (Alpbach, Austria)
Invited Plenary Session Speaker to NIH BECON Symposium, Biomedical Imaging:
Visualizing the Future of Biology and Medicine, on “Clinical Prospects for Imaging and
Managing Angiogenesis in Cancer and Atherosclerosis”, June 25, 1999 (Bethesda, MD)
Invited Speaker to National Cancer Institute sponsored Symposium, Imaging in 2020
Conference, on “Molecular and cellular imaging of the cardiovascular system”, September 1999
(Jackson Hole, WY)
Program Chairman and Invited Speaker for Society for Cardiovascular MR Annual Scientific
Session, January 2000 (Atlanta, GA)
Invited Speaker at the 2000 “Metals in Biology” Gordon Conference on “Molecular and
Cellular Imaging of the Cardiovascular System”, January 2000 (Ventura, CA)
Invited Panelist and Speaker to the National Cancer Institute sponsored symposium,
“Angiogenesis Imaging Methodology: Role of Imaging in Clinical Trials of Anti-angiogenic
Therapy in Oncology” (“AIM for Clinical Trials”), February 2000 (Lake Tahoe, NV)
Invited Speaker and Session Chair at the 2000 Meeting of the World Congress on Medical
Physics and Biomedical Engineering, July 2000 (Chicago, IL)
Invited Speaker at National Cancer Institute, Second National Forum on Biomedical
Imaging in Oncology: “Overview of angiogenesis: Ultrasound”, September 2000 (Alexandria,
VA)
Invited Speaker at Biomedical Engineering 2000 Meeting on “High frequency myocardial
tissue characterization”, October 2000 (Seattle, WA)
5
2000
2000
2001
2001
2001
2001
2002
2002
2002
2002
2002
2002
2002
2002
2002
2003
2003
2003
2003
Invited Plenary Speaker at the IEEE-UFFC Ultrasonics Symposium on “Targeted contrast
agents for molecular diagnosis”, October 2000 (San Juan, PR)
Invited Speaker at AHA/SCMR on “How to get started in Cardiac MR”, November 2000
(New Orleans, LA)
Invited Speaker at University of Missouri-Columbia’s Cardiovascular Day on “Imaging
molecular epitopes responsible for angiogenesis with novel targeted contrast agents”, February
2001 (Columbia, MO)
Invited Speaker at American Institutes for Ultrasound in Medicine on “Ultrasonic molecular
imaging and intervention”, March 2001 (Orlando, FL)
Invited Plenary Speaker at International Society of Magnetic Resonance in Medicine
(ISMRM) on “Molecular imaging with targeted contrast agents”, April 2001 (Glasgow,
Scotland)
Invited Speaker at the Contrast Media Research 2001 Meeting on “Liquid perfluorocarbon
nanoparticles: a “new” class of blood pool contrast agents for ultrasound that exhibit marked
and prolonged blood contrast enhancements in vivo with Power Doppler Harmonic (PDH)
imaging”, October 2001 (Capri, Italy)
Invited Speaker at the SCMR 5th Annual Scientific Sessions on “Molecular targets for
detection of atherosclerosis”, January 2002 (Orlando, FL)
Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of
Cardiology on “Molecular Imaging”, March 2002 (Atlanta, GA)
Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of
Cardiology at Anatomic and Physiological Lesion Assessment: Investigational and Therapeutic
Session on "MRI Applications to Coronary Artery Evaluation", March 2002 (Atlanta, GA)
Invited Plenary Speaker at the 2002 Annual Scientific Sessions American College of
Cardiology at Magnetic Resonance Imaging for Coronary Imaging and Therapy Session, March
2002 (Atlanta, GA)
Invited Plenary Speaker at the 25th Annual Conference for Ultrasonics in Biophysics and
Bioengineering's Session on Imaging with Contrast Agents II, May 2002 (Allerton Park, IL)
Plenary Speaker at the Society of Molecular Imaging Meeting on "Molecular Imaging with
nanoparticles", August 2002 (Boston, MA)
Invited Speaker at Board of External Advisors (BEA) meeting of the NHLBI, September
2002 (Washington, DC)
Invited Speaker at the 3rd Annual BioMEMs & Biomedical Nanotechnology World 2002
meeting, September 2002, (Florida)
Invited Speaker at AHA on "Thrombus-Avid MR Contrast Agents in Molecular Basis for
Cardiac Imaging", November 2002 (Orlando, FL)
Invited Speaker at the SCMR Annual Scientific Sessions on "CMR in Clinical DecisionMaking", February 2003 (Lake Buena Vista, FL)
Invited Speaker at the 52nd Annual Scientific Session of the American College of
Cardiology on "A Primer of Magnetic Resonance and Computed Tomography for the
Practitioner: Certification/Accreditation/Reimbursement", March 2003 (Chicago, IL)
Invited Lecturer at IEEE-UFFC Conference on "Transducer Design, High Frequency
Ultrasound for Molecular Imaging", March 2003 (Los Angeles, CA)
Speaker at International Society of Magnetic Resonance in Medicine Molecular Imaging
Symposium, "Ultrasound Molecular Imaging", June 2003 (Bordeaux, France)
6
2003
2003
2003
2003
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
2004
2005
2005
2005
2005
Scientific Program Committee and Session Moderator for Society for Molecular Imaging,
August 2003 (San Francisco, CA)
Invited Speaker at the European Society of Cardiology's Congress 2003 on "Targeting
Thrombi and Plaques", August 2003 (Vienna, Austria)
Speaker and Moderator: Gordon Research Conference on "Assisted Circulation",
September 2003 (Big Sky, MT)
Keynote Speaker: UCSD Biomedical Engineering Scientific Symposium on "Molecular
Imaging", November 2003 (San Diego, CA)
Invited Speaker at the SCMR Annual Scientific Meeting "CMR in the United States: What does
it take?", February 2004 (Barcelona, Spain)
Keynote Address: National Cancer Institute Symposium "Nanotechnology and Cancer
Imaging", Fred Hutchinson Cancer Institute, March 2004 (Seattle, WA)
Invited Speaker at the 3rd Scientific Meeting of the TMJ Association’s Advancing Diagnostic
Approaches for TMJ Disorders on “Molecular Imaging with Targeted Nanoparticles”, May
2004 (Bethesda, MD)
Invited Speaker at International Society of Magnetic Resonance in Medicine on "CMR and
Cardiovascular Disease", May 2004 (Kyoto, Japan)
Invited Speaker at International Vulnerable Plaque Society 2nd Annual Meeting on "Molecular
Imaging of Vulnerable Plaque", June 2004 (Taormina, Italy)
Invited Speaker at Annual Scientific Meeting American Institute of Ultrasound in Medicine on
"Ultrasound Contrast Agents for Molecular Imaging", June 2004 (Phoenix, AZ)
Invited Speaker at the BioMEMS and NANOtech World 2004 Conference, August 2004
(Washington, DC)
Invited Plenary Speaker to European Society of Cardiology: "Cardiovascular Molecular
Imaging", August 2004 (Munich, Germany)
Invited Speaker at the 8th Annual Scientific Meeting of the Heart Failure Society of America, on
“Targeted Imaging and Therapeutics”, September 2004 (Toronto, Canada)
Invited Speaker at the 4th International Ultrasonic Biomedical Microscanning Conference on
“Targeted Contrast Agents”, September 2004 (Arden House, NY)
Invited Speaker at the 2nd Annual National Academies Keck Futures Initiative “Designing
Nanostructures” Pre-Conference, September 2004 (Washington, DC)
Invited Speaker at the Transcatheter Cardiovascular Therapeutics (TCT) 2004 Conference,
September 2004 (Washington, DC)
Invited Speaker, Barbara Davis Diabetes Foundation Scientific Session & Benefit, “Molecular
Imaging”, October 2004 (Beverly Hills, CA)
Invited Speaker at the 19th Annual Advances in Contrast Ultrasound/Bubble Course 2004,
November 2004 (Chicago, IL)
Invited Speaker at Society for Cardiovascular Magnetic Resonance 8th Annual Scientific
Sessions 2005, “Molecular Imaging by CMR”, January 2005 (San Francisco, CA)
Invited Speaker at the European Congress of Radiology 2005 on “Targeted MR contrast
agents”, March 2005 (Vienna, Austria)
Invited Speaker at the 69th Annual Scientific Meeting of the Japanese Circulation Society,
“Molecular Imaging and Targeted Therapeutics”, March 2005 (Yokohama, Japan)
Invited Speaker, International Society of Magnetic Resonance in Medicine, “MRI and
Molecular Imaging”, May 2005 (Miami, FL)
7
2005
2005
2005
2005
2005
2005
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
2006
Invited Speaker, German Heart Institute Berlin, May 2005 (Berlin, Germany)
Invited Speaker, 3rd Vulnerable Plaque Meeting, June, 2005 (Capri, Italy)
Invited Speaker, Congressional Biomedical Research Caucus, “What is Nanotechnology and
How Might it be Useful in Clinical Practice? An Example of Heart Disease”, July 2005,
(Washington, DC)
Invited Speaker, 53rd Scientific Sessions of the Japanese College of Cardiology, “Advance of
Intervention with Imaging Systems”, September 2005 (Osaka, Japan)
Invited Speaker, XXVI National Congress of the Italian Society of Invasive Cardiology (GISE),
“Seeing within: Molecular imaging of the vulnerable plaque”, September 2005, (Genoa, Italy)
Invited Speaker, AACR/NCI/EORTC International Conference on Molecular Targets and
Cancer Therapeutics: Discovery, Biology, and Clinical Applications, “Molecular Imaging and
Targeted Therapeutics with Perfluorocarbon Nanoparticles”, November 2005 (Philadelphia,
PA)
Invited Speaker, Preconference Society for Cardiovascular Magnetic Resonance 9th Annual
Scientific Sessions, “Valvular function/flow: MR challenges echocardiography”, January 2006
(Miami, FL)
Plenary Speaker, Japanese Ministry of Health Symposium, “Molecular Medicine and the Future
of Medicine”, February 17, 2006 (Tokyo, Japan)
Invited Speaker, American College of Cardiology Annual Scientific Sessions, “Aortic and
mitral valve dysfunction and shunts by MRI: Why quantification matters”, March 12, 2006
(Atlanta, GA)
Invited Speaker, Fourth International Symposium on Targeted Anticancer Therapeutics (TAT),
March 18, 2006 (Amsterdam, Netherlands)
Invited Speaker, Transcatheter Therapeutics Symposium, “Molecular Imaging: Magnetic
resonance nanoparticles for enhanced imaging of vulnerable plaque and developing collaterals”,
April 6, 2006 (Washington, DC)
Keynote Address, Ohio Academy of Science Annual Scientific Sessions, “Targeted
nanosystems for diagnosis and therapy,” April 22, 2006 (Dayton, OH)
Invited speaker, University of Illinois Urbana-Champaign Annual Nanotechnology Workshop,
“Molecular Imaging and targeted therapy of cardiovascular disease and cancer”, May 2006
(Urbana Champaign, IL)
Invited Speaker, EuroPCR 2006, “Molecular imaging of cardiovascular disease”, May 18, 2006
(Paris, France)
Plenary Speaker, Washington University Symposium on Advances in Targeted Therapy, “Smart
nanoparticles for molecular imaging and targeted therapy of cancer”, May 2006 (St. Louis, MO)
Invited Speaker, Deutsches Herz Centrum Symposium on Molecular Imaging, June 23, 2006
(Berlin, Germany)
Plenary Speaker, First IDEA League Summer School: Biotechnology and Bioengineering
Applications in Medicine, September 21, 2006 (Ascona, Switzerland)
Plenary Speaker, Materials, Medicine, and Nanotechnology Summit: Plenary Session IVNanotechnology, October 2006 (Cleveland, OH)
Invited Speaker, Cambridge Healthtech Institute’s Targeted Nanodelivery, October 2006
(Baltimore, MD)
Invited Speaker, 2006 Cancer Patient Education Network (CPEN) 2006; Annual Conference,
October 2006 (St. Louis, MO)
8
2006
2006
2006
2006
2007
2007
2007
2007
2007
2007
2007
2007
2007
2007
2008
Invited Speaker, American Heart Association Scientific Sessions 2006, “Molecular imaging of
vulnerable plaques and developing collaterals,” November 2006 (Chicago IL)
Invited Speaker, 2006, Association of Molecular Pathology Annual Meeting, “Ligand targeted
nanoparticles for cancer diagnosis and therapy”, November 2006 (Orlando, Florida)
Invited Speaker, Global Cardiovascular Interventions XVIIth International Course, “Magnetic
resonance imaging for detection of unstable coronary plaque”, November 2006 (Frankfurt,
Germany)
Reneman Laureate Lecturer, CARIM Symposium (Cardiovascular Research Institute of
Maastricht), “Molecular Imaging and Drug Delivery for Cancer and Cardiovascular Disease
With Targeted Nanoparticles”, November 29, 2006 (Maastricht, Netherlands)
Invited Speaker, 71st Annual Scientific Meeting of the Japanese Circulation Society (JCS),
March 2007 (Kobe, Japan)
Invited speaker, Symposia Biomedica, “Nanotechnology for molecular imaging and targeted
therapeutics”, March 21, 2007 (Aachen, Germany)
Invited Speaker, National Science Teachers Association Annual Conference, March 25, 2007
(St. Louis, MO)
Invited speaker, American College of Cardiology Annual Scientific Sessions, “CMR in valve
disease”, March 25, 2007 (New Orleans, LA)
Plenary speaker, American Society of Clinical Oncology Annual Scientific Sessions, May 3,
2007 (Chicago, IL)
Invited speaker, International Society of Magnetic Resonance in Medicine Annual Scientific
Sessions, “Gadolinium nanoparticle contrast agents” May 24, 2007 (Berlin, Germany)
Keynote Lecture, American Chemical Society 234th Annual Scientific Meeting, Nanostructured
Fluorocarbons. Smart modules for self assembly processes and synthetic Protocols, Aug 1923, 2007 (Boston, MA)
Keynote Address, William Beaumont Hospital’s 16th Annual Symposium on Molecular
Pathology, DNA Technology in the Clinical Laboratory, Targeted nanosystems for molecular
imaging and personalized therapeutics, Sep 27, 2007 (Troy, MI)
Special Lecture, 19th Transcatheter Cardiovascular Therapeutics Meeting, Nanoparticles for
molecular imaging and targeted therapeutics: Application for vulnerable plaque detection and
treatment, Oct 2007 (Washington, DC)
Invited speaker, Nanotechnology in Biology & Medicine, Nanoemulsions for multimodal
molecular imaging and targeted therapeutics, Nov 2007 (Charlotte, NC)
Invited speaker, 11th Annual SCMR Scientific Sessions, Gd-Labeled Nanoparticles for
Moelcular MRI and Fluorine Imaging: An Alternative Approach to Mlecular MRI, Jan 2008
(Los Angeles, CA)
Consulting/Corporate Relationships
Consultant: Philips Medical Systems, Dow Chemical, and Bristol-Myers Squibb
Founder: Kereos, Inc., St. Louis, MO; Board of Directors, and Chairman of S.A.B.
Founder: PixelEXX, Inc., St. Louis, MO; Board of Directors, and acting Co-President
Patents (US filings only: partial listing; disclosures not included)
1)
“Avidin-biotin conjugated emulsions as a site specific binding system” (issued
11/25/97, #5,569,907)
9
2)
3)
4)
5)
6)
7)
8)
9)
10)
11)
12)
13)
14)
15)
16)
17)
18)
19)
20)
21)
22)
23)
24)
25)
26)
27)
28)
29)
30)
31)
“Method of MRI using avidin-biotin conjugated emulsions as a site specific binding
system” (issued 7/14/98, #5,780,010)
“Site specific binding systems, imaging compositions, and methods” (issued, 11/23/99,
#5,989,520)
“Site specific binding system, imaging compositions and methods” (issued
9/28/99, #5,958,371)
“Ligand-targeted emulsions carrying bioactive agents” (issued 1/13/04, #6,676,963)
“Site specific binding system, nuclear imaging compositions, and methods” (issued 4/15/03,
#6,548,046)
“Enhanced ultrasound detection with temperature-dependent contrast agents”
(issued 2/20/07, #7,179,449)
"Paramagnetic particles that provide improved relaxivity" (issued 3/22/05, #6,869,591)
"Site-Specific Binding System, Imaging Compositions and Methods" (issued 11/23/04,
#6,821,506)
“ECG triggered MR imaging method and apparatus” (issued February, 1999,
#W09904688)
“Methods for targeted drug delivery” (issued 3/6/07, #7,186,399)
“Paramagnetic particles that provide improved relaxivity” (issued 6/26/07, #7,235,227)
“Blood clot-targeted nanoparticles” (issued 5/22/07, #7,220,401)
"Method and Apparatus for Intracorporeal Medical Imaging Using a Self-Tuned Coil"
(Issued)
"Method and Apparatus for Intracorporeal Medical Imaging Using Self-Tuned Coils"
(Docket 66435/40272, filed 6/5/03)
“Integrin targeted imaging agents” issued 8/14/07, #7,255,875)
“Targeted nanoparticles” (#60/400,452, filed 7/31/02)
“Chelating agents with lipophilic carriers” (issued 10/9/07, #7,279,150)
“Relaxivity of paramagnetic nanoparticles for molecular imaging depends on chelate
conformation” (filed 3/26/02, 60/368,100)
“Emulsion particles for imaging and therapy and methods of use thereof” (filed 08/08/03,
60/493,492)
“Enhanced drug delivery” (filed 11/19/03, 60/523,833)
“Improved efficacy and safety of targeted particulate agents with decoy systems” (filed
2/10/04, 60/543,761)
“Emulsion particles for imaging and therapy and methods of use thereof” (filed 8/6/04,
#10/913,846)
“System and methods for ultrasonic characterization of internal body conditions using
information theoretic signal receivers” (filed 6/2005)
“Multifunctional nanoscopy for imaging cells” (provisional filed 9/2006)
“Cell labeling with perfluorocarbon nanoparticles for magnetic resonance imaging and
spectroscopy” (provisional filed 2/24/2006)
“MR coronary angiography with a fluorinated nanoparticle contrast agent 1.5T” (filed 3/4/2005)
“Methods to ameliorate and image angioplasty induced vascular injury” (filed 2/28/07)
“Cytotoxic peptides on nanoparticle carriers for therapy” (filed)
“Multispectral molecular imaging with fluorine-containing agents” (filed 6/14/07, #11/762,903)
“Lipid-encapsulated magnetic nanoparticle” (filed 10/9/07, #60/978,678)
10
32)
33)
34)
“Nano-bialys particles and uses thereof” (filed 10/9/07, #60/978,679)
“Integrin targeted imaging agents” (filed, #1 11305,416)
“Targeted cell-penetrating peptides” (submitted, docket 295003007300)
Current Research Support
Current Governmental
U54 (CA119342) National Institutes of Health, September 2005 to August 2010; Total Award
$16,643,205: The Siteman Center of Cancer Nanotechnology Excellence. Principal Investigator:
Samuel A. Wickline, M.D., $2,330,739 (direct), 30% effort.
RO1 (HL073646) National Institutes of Health, July 2004 to June 2009; Total Award $6,357,997:
Methods in molecular imaging and targeted therapeutics. Principal Investigator: Samuel A. Wickline,
MD., $1,149,071/yr (direct), 35% effort
N01-CO-37007 National Cancer Institute, September 2003 to September 2007; Total Award
$5,097,055: Novel Technologies for Noninvasive Detection, Diagnosis and Treatment of Cancer.
Principal Investigator: Gregory M. Lanza, M.D., Ph.D., $1,130,806 (direct), 5% effort.
R01 (EB001704) National Institutes of Health, December 2003 to November 2008; Total Award
$905,512: Molecular Imaging of Angiogenesis by MRI. Principal Investigator: Patrick Winter, Ph.D.,
$157,500/yr (direct), unpaid consultant.
RO1 (HL78631) National Institutes of Health, September 2004 to August 2008; Total Award
$1,504,116: Combined therapeutic-imaging agent for atherosclerosis. Principal Investigator: Gregory
M. Lanza, M.D., Ph.D., $244,125 (direct), 10% effort.
P20 (RR020643) National Institutes of Health, September 2004 to July 2007; Total Award
$1,747,250: Planning Interdisciplinary Studies of the Diabetic Heart. Principal Investigator: Daniel
Kelly, M.D., $373,269 (direct), 5% effort.
P50 (HL083762) National Institutes of Health, May 2006 to Mar 2011; Total Award $10,243,987:
SCCOR in Metabolic Syndrome and Vascular Disease. Principal Investigator: Clay Semenkovich,
M.D. Core B: Clinical Imaging Core. Principal Investigator Core B: Samuel A. Wickline, M.D.
$258,087 (direct), 5% effort.
Current Nongovernmental
Philips Medical Systems, “Cardiovascular magnetic resonance imaging”, 2000-2009 (~$370,000/yr in
personnel/equipment/service contracts) for implementation of a new Cardiac MRI program at BarnesJewish Hospital within the Department of Medicine, Division of Cardiology. Three PhD Engineers
and Physicists are supported with these monies, as well as equipment and travel expenses. P.I.: Samuel
Wickline, M.D. Total Award $10 million/5 yr.
11
Teaching
Graduate Level Courses
Coursemaster: BME 502, “Cardiovascular MRI: From Physics to Practice”
Spring semester yearly
Coursemaster: BME/DBBS #?? “Topics in Nanotechnology” Fall 2007
Annual Symposia
Director: Washington University Cardiac MRI Training Course: "A Practical Course", MarchApril yearly
Mentorship
Current degree candidates
Alex Waters, M.S. (Ph.D. BME: 2008)
Neelesh Soman, M.S. (Ph.D. BME: 2008)
Megan Kaneda, M.S. (Ph.D. BME: 2008)
Kejia Cai, M.S. (Ph.D. BME: 2009)
Lei Zhang, M.S. (Ph.D. BME: 2009)
Jacob Meyerson (Ph.D. BME: 2010)
Current postdoctoral
Steve Baldwin, Ph.D.; Ultrasound
Hua Pan, Ph.D., Nanotechnology
Previous degree candidates
Kathy Partlow, Ph.D. (2000-2007); UIUC post-doctoral, Urbana, IL
Anne Neubauer, Ph.D. (2004-2007); Philips Medical Systems
Jason Brant, M.S. (20005-2007); Medical Student, Washington University
Junjie Chen, D.Sc. (2000-2004); Staff Scientist, Washington Univ. (Wickline lab)
Wei Liu, D.Sc. (2000-2004); Clinical Sites Research Scientist, Philips Research USA
Previous Postdoctoral
Marvin Ashford, M.D. (2002-2004); Private Practice, Little Rock, AR
Jina Chung, M.D. (2003-2006); Cardiologist, Los Angeles Cardiology Associates
Catherine Dent, M.D. (1998-2000); Assoc Prof of Pediatrics, Univ. of Ohio, Cincinnati, OH
Cuong Nguyen, M.D. (1996-1999); Practicing Physician; Los Vegas, NV
Gregory Lanza, M.D. (1994-1999); Assoc Prof of Medicine and BME, Washington University
Angel Lopez-Candales, M.D. (1993-1996); Assoc Prof of Cardiology, Univ. of Pittsburg, PA
Angel Sharkey, M.D. (1992-1997); Assoc Prof of Pediatrics, Washington University
Christopher Hall, Ph.D. Physics (1992-1996); Laboratory Director, Philips Medical Systems,
NY, NY
Glenn Davison, M.D. (1992-1994); Private Practice, Chesterfield, MO
Dino Recchia, M.D. (1991-1994); Private Practice, Travers City, MI
Lori Bridal, Ph.D. Physics (1990-1994); Research Scientist, Paris, FR
Victor Davila, M.D. (1998-2000); Prof of Medicine and Radiology, Washington University
12
Thesis Committee
Physics: Scott Handley, Mark Holland, Brent Hoffmeister, Lori Bridal, Mark Kaufmann, Ed Verdonk,
Kyle Holman, Chris Hall, Joel Moberly, Jon Marsh, Steve Baldwin, and Charles Chung
BME: Andy Hall, Jon Chia, Brad Wacker, Hua Pan
Computer Science: Richard Souvenier (PhD 2006)
Bibliography
1.
McDanal JT, Wickline SA, Suehiro GT, Thomas VE, McNamara JJ: Further studies on the
significance of microaggregates in stored blood. Surg Forum. 1975; 26: 214.
2.
Wickline SA, McNamara JJ: Vectorcardiographic quantification of infarct size. Surg
Forum 1977; 28: 244-245.
3.
Wickline SA, Soeter JR, McNamara JJ: Oxygenation of the cerebral and coronary
circulation with right axillary artery perfusion during venoarterial bypass in primates. Ann
Thoracic Surg 1977; 24: 560-565.
4.
Wickline SA, McNamara JJ: Vectorcardiographic quantification of infarct size in
baboons. Circulation 1978; 57: 910-920.
5.
Ruf W, McNamara JJ, Suehiro GT, Wickline SA: Platelet trapping in myocardial infarct in
baboons: Therapeutic effect of aspirin. Am J Cardiol 1980; 46: 405-412.
6.
Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: The dependence of
myocardial ultrasonic backscatter on contractile performance. Circulation 1985; 72: 183-192.
7.
Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: A relationship between
ultrasonic integrated backscatter and myocardial contractile function. J Clin Invest 1985; 76:
2151-2160.
8.
Thomas LJ III, Wickline SA, Perez JE, Sobel BE, Miller JG: A real-time integrated backscatter
measurement system for quantitative cardiac tissue characterization. IEEE Trans on
Ultrasonics, Ferroelectrics, and Frequency Control 1986; 33: 27-32.
9.
Wickline SA, Thomas LJ III, Miller JG, Sobel BE, Perez JE: Sensitive detection of the effects
of reperfusion on myocardium by ultrasonic tissue characterization with integrated backscatter.
Circulation 1986; 74: 389-400.
10.
Vered Z, Mohr GA, Barzilai B, Gessler CG, Wickline SA, Wear KA, Shoup TA, Weiss AN,
Sobel BE, Miller JG, Perez JE: Ultrasonic integrated backscatter characterization of remote
myocardial infarction in human subjects. J Am Coll Cardiol 1989; 13: 84-91.
13
11.
Thomas LJ III, Barzilai B, Perez JE, Sobel BE, Wickline SA, Miller JG: Quantitative real-time
imaging of myocardium based on ultrasonic integrated backscatter. IEEE Trans on Ultrasonics,
Ferroelectrics, and Frequency Control 1989; 36: 466-470.
12.
Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: Differentiation
between acutely ischemic myocardium and zones of completed infarction in dogs on the basis
of frequency-dependent backscatter. J Acoust Soc Am 1989; 85: 2634-2641.
13.
Milunski MR, Canter CE, Wickline SA, Sobel BE, Miller JG, Perez JE: Cardiac cycledependent variation of integrated backscatter is not distorted by abnormal myocardial wall
motion in human subjects with paradoxical septal motion. Ultrasound Med Biol 1989; 15: 311317.
14.
Milunski MR, Mohr GA, Wear KA, Sobel BE, Miller JG, Wickline SA: Early identification
with ultrasonic integrated backscatter of viable but stunned myocardium in dogs. J Am Coll
Cardiol 1989; 14: 462-471.
15.
Milunski MR, Mohr GA, Perez JE, Vered Z, Wear KA, Gessler CJ, Sobel BE, Miller JG,
Wickline SA: Ultrasonic tissue characterization with integrated backscatter. Acute myocardial
ischemia, reperfusion, and stunned myocardium in patients. Circulation 1989; 80: 491-503.
16.
Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: Contraction- related
variation in frequency dependence of acoustic properties of canine myocardium. J Acoust Soc
Am 1989; 86: 2067-2072.
17.
Wickline SA, Barzilai B, Thomas LJ III, Saffitz JE: Quantification of intimal and medial
thickness of human coronary arteries by acoustic microscopy. Coronary Artery Disease 1990;
1: 375-381.
18.
Verdonk ED, Wickline SA, Miller JG: Quantification of the anisotropy of ultrasonic
quasilongitudinal velocity in normal human and canine myocardium with comparison to
anisotropy of integrated backscatter. IEEE Ultrason Symp 1990; 90CH2938-9: 1349-1352.
19.
Wear KA, Milunski MR, Wickline SA, Perez JE, Sobel BE, Miller JG: The effect of frequency
on the magnitude of cyclic variation of backscatter in dogs and implications for prompt
detection of acute myocardial ischemia. IEEE Trans on Ultrasonics, Ferroelectrics, and
Frequency Control 1991; 38: 498-502.
20.
Wickline SA, Verdonk ED, Miller JG: Three-dimensional characterization of human
ventricular myofiber architecture by ultrasonic backscatter. J Clinical Invest 1991; 88: 438446.
21.
Hoffmeister BK, Wong AK, Verdonk ED, Wickline SA, Miller JG: Quantitative assessment of
the directional dependence (anisotropy) for ultrasonic backscatter in human tendon. IEEE
Ultrason Symp 1991; 91CH3079-1: 1127-31.
14
22.
Wickline SA, Verdonk ED, Wong AK, Shepard RK, Miller JG: Structural remodeling of
human myocardial tissue after infarction. Quantification with ultrasonic backscatter.
Circulation 1992; 85: 259-268.
23.
Wickline SA, Verdonk ED, Sobel BE, Miller JG: Identification of human myocardial
infarction in vitro based on the frequency dependence of ultrasonic backscatter. J Acoust Soc
Am 1992; 91: 3018-25.
24.
Wong AK, Verdonk ED, Hoffmeister BK, Miller JG, Wickline SA: Detection of unique
transmural architecture of human idiopathic cardiomyopathy by ultrasonic tissue
characterization. Circulation 1992; 86: 1108-1115.
25.
Shepard RK, Miller JG, Wickline SA: Quantification of atherosclerotic plaque composition in
cholesterol-fed rabbits with 50 MHz acoustic microscopy. Arteriosclerosis and Thrombosis
1992; 12: 1227-1234.
26.
Verdonk ED, Wickline SA, Miller JG: Anisotropy of ultrasonic velocity and elastic properties
in normal human myocardium. J Acoust Soc Am 1992; 92: 3039-3050.
27.
Wickline SA, Shepard RK, Recchia D, Verdonk ED, Miller JG: Quantification of
ultrasonic anisotropy of scattering from myocardium in vitro and in vivo. Proc IEEE
Ultrason Symp 1992; 92CH3118-7: 1083-1086.
28.
Wong AK, Osborn TA, Miller JG, Wickline SA: Quantification of ventricular remodeling in
the tight-skin mouse cardiomyopathy with acoustic microscopy. Ultrasound Med Biol 1993; 19:
365-374.
29.
Recchia D, Wickline SA: Ultrasonic tissue characterization of blood during stasis and
thrombosis with a real-time linear-array backscatter imaging system. Coronary Artery Disease
1993; 4: 987-994.
30.
Recchia D, Miller JG, Wickline SA: Quantification of ultrasonic anisotropy in normal
myocardium with lateral gain compensation of two-dimensional integrated backscatter images.
Ultrasound Med Biol 1993; 19: 497-505.
31.
Wickline SA, Shepard RK, Daugherty A: Quantitative ultrasonic characterization of lesion
composition and remodeling in atherosclerotic rabbit aorta. Arteriosclerosis and Thrombosis
1993; 13: 1543-1550.
32.
Bridal SL, Recchia D, Miller JG, Wickline SA: Anisotropy of apparent integrated backscatter,
signal loss and backscatter coefficient at 30 to 45 MHz in canine papillary muscle. Ultrasonic
Imaging 1993; 15: 155-156.
15
33.
Davison G, Hall CS, Scott MS, Miller JG, Wickline SA: Cellular mechanisms of captoprilinduced matrix remodeling in Syrian hamster cardiomyopathy. Circulation 1994; 90: 1334-42.
34.
Hoffmeister BK, Verdonk ED, Wickline SA, Miller JG: Effect of collagen on the anisotropy
of quasi-longitudinal mode ultrasonic velocity in fibrous soft tissues: a comparison of fixed
tendon and fixed myocardium. J Acoust Soc Am 1994; 96: 1957-64.
35.
Wickline SA, Miller JG, Recchia D, Sharkey AM, Bridal L, Christy D: Beyond intravascular
imaging: Quantitative ultrasonic tissue characterization of vascular pathology Proc IEEE
Ultrason Symp 1994; 94CH3468-6: 1589-1597.
36.
Perez JE, Miller JG, Holland MR, Wickline SA, Waggoner AD, Barzilai B, Sobel BE:
Ultrasonic tissue characterization: Integrated backscatter imaging for detecting myocardial
structural properties and on-line quantitation of cardiac function. Am J Card Imaging 1994; 8:
106-12.
37.
Rose JH, Kaufmann MR, Wickline SA, Hall CS, Miller JG: A proposed microscopic elastic
wave theory for ultrasonic backscatter from myocardial tissue. J Acoust Soc Am 1995; 97: 656668.
38.
Recchia D, Hall CS, Shepard RK, Miller JG, Wickline SA: Mechanisms of the viewdependence of ultrasonic backscatter from normal myocardium. IEEE Trans on Ultrasonics,
Ferroelectrics, and Frequency Control 1995; 42: 91-98.
39.
Recchia D, Kouchoukos NT, Bosner MS, Wickline SA: Sensitive detection of abnormal aortic
architecture in Marfan Syndrome with high-frequency ultrasonic tissue characterization.
Circulation 1995; 91: 1036-1043 (accompanied by editorial comment).
40.
Recchia D, Abendschein DR, Saffitz JE, Wickline SA: The biological behavior of balloon
hyperinflation-induced arterial lesions in hypercholesterolemic pigs depends on the presence of
foam cells. Arteriosclerosis Thrombosis Vasc Biol 1995; 15: 924-929.
41.
Davison G, Hall CS, Miller JG, Scott M, Wickline SA: Ultrasonic tissue characterization
detects captopril-induced remodeling in experimental dilated cardiomyopathy. Ultrasound Med
Biol 1995; 21: 853-860.
42.
Lopez-Candales A, Scott MS, Wickline SA: Cholesterol feeding modulates spatial expression
of TGF-ß1 and ß2 in aortas of Watanabe rabbits. Cytokine 1995; 7: 554-561.
43.
Williams EB, Halpert I, Wickline SA, Davison G, Parks WC, Rottman JN: Osteopontin
expression is increased in the heritable cardiomyopathy of Syrian Hamsters. Circulation 1995;
92: 705-709.
16
44.
Hoffmeister BK, Wong AK, Verdonk ED, Wickline SA, Miller JG: Comparison of the
anisotropy of apparent integrated ultrasonic backscatter from fixed human tendon and fixed
human myocardium. J Acoust Soc Am 1995; 97: 1307-1313.
45.
Hoffmeister BK, Handley SM, Verdonk ED, Wickline SA, Miller JG: Estimation of the elastic
stiffness coefficient C13 of fixed tendon and fixed myocardium. J Acoust Soc Am 1995; 97:
3171-3176.
46.
Christy DH, Wallace KD, Lanza GM, Holland MR, Hall CS, Scott MJ, Cacheris WP, Gaffney
PJ, Miller JG, Wickline SA: Quantitative intravascular ultrasound: Demonstration using a
novel site targeted acoustic contrast agent. Proc IEEE Ultrason Symp 1995; 95CH35844:
1125-1128.
47.
Verdonk ED, Hoffmeister BK, Wickline SA, Miller JG: Anisotropy of the slope of ultrasonic
attenuation in formalin fixed human myocardium. J Acoust Soc Am 1996; 99: 3837-3843.
48.
Halpert I, Sires UI, Roby JD, Potter-Perigo S, Wight TN, Shapiro SD, Welgus HG, Wickline
SA, Parks WC: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture
in atherosclerotic lesions and localizes to areas of veriscan deposition, a proteoglycan substrate
for the enzyme. Proc Nat Acad Sci 1996; 93: 9748-9753.
49.
Bridal SL, Wallace KD, Trousil RL, Wickline SA, Miller JG: Frequency dependence of
acoustic backscatter from 5 to 65 MHz (0.06 < ka < 4.0) of polystyrene beads in agarose. J
Acoust Soc Am 1996; 100: 1841-1848.
50.
Lopez-Candales A, Holmes DR, Scott MJ, Thompson RW, Wickline SA: Effects of ultraviolet
light in vascular cells in vitro and in intact atherosclerotic explants: potential role of apoptosis
in vascular biology. Biochem Cell Biol 1996; 74: 333-345.
51.
Abendschein D, Recchia DR, Meng YY, Oltrona L, Wickline SA, Eisenberg PR: Inhibition of
thrombin attenuates stenosis after arterial injury in minipigs. J Am Coll Cardiol 1996; 28:
1849-1855.
52.
Lanza GM, Wallace KD, Scott MJ, Cacheris WP, Abendschein DR, Christy DH, Sharkey AM,
Miller JG, Gaffney PJ, Wickline SA: A novel site-targeted ultrasonic contrast agent with broad
biomedical application. Circulation 1996; 94: 3334-3340.
53.
Hoffmeister BK, Handley SM, Wickline SA, Miller JG: Ultrasonic determination of the
anisotropy of Young’s modulus of fixed tendon and fixed myocardium. J Acoust Soc Am
1996; 100: 3933-3940.
54.
Lopez-Candales A, Scott MJ, Wickline SA: Different temporal and spatial distribution of TGFbeta-1 and TGF-beta-2 in rabbit vascular tissue—potential role in normal vessel growth and
maturation. Cytokine 1996; 8: 675-685.
17
55.
Lopez-Candales A, Scott MJ, Wickline SA: In vitro exposure of murine macrophages to
ultraviolet light induces apoptosis. Boletin – Asociacion Medica de Puerto Rico 1996; 88: 5762.
56.
Hall CS, Verdonk ED, Wickline SA, Perez JE, Miller JG: Anisotropy of the apparent
frequency dependence of backscatter in formalin fixed human myocardium. J Acoust Soc Am
1997; 101: 563-568.
57.
Oltrona L, Speidel CM, Recchia D, Wickline SA, Eisenberg PR, Abendschein DR:
Inhibition of tissue factor-mediated coagulation markedly attenuates stenosis after ballooninduced arterial injury in minipigs. Circulation 1997; 96: 646-652.
58.
Wickline SA: Advances in ultrasound methods for high-resolution imaging of the
cardiovascular system. Trends Cardiovas Med 1997; 7: 168-174.
59.
Lanza GM, Wallace KD, Fischer SE, Christy DH, Scott MJ, Trousil RL, Cacheris WP, Miller
JG, Gaffney PJ, Wickline SA: High-frequency ultrasonic detection of thrombi with a targeted
contrast system. Ultrasound Med Biol 1997; 23: 863-870.
60.
Lanza GM, Scott MJ, Davison G, Hall CH, Christy DH, Miller JG, Wickline SA: Angiotensin
II receptor blockade in Syrian hamster (TO-2) cardiomyopathy does not affect microscopic
cardiac material properties: Implications for mechanism of tissue remodeling. Cardiovas Drugs
Ther 1997; 11: 521-529.
61.
Davison G, Whittaker P, Wickline SA: Captopril therapy limits ventricular remodeling but
does not alter myocardial collagen fiber morphology of cardiomyopathic hamsters. Cardiovasc
Pathol 1997; 6: 307-313.
62.
Lopez-Candales A, Holmes DR, Liao S, Scott MJ, Wickline SA, Thompson RW:
Decreased vascular smooth muscle cell density in medial degeneration of human abdominal
aortic aneurysms. Am J Pathol 1997; 150: 993-1007.
63.
Hall CS, Lanza GM, Rose JH, Kaufmann RJ, Fuhrhop RW, Handley SH, Waters KR, Miller
JG, Wickline SA: Experimental determination of phase velocity of perfluorocarbons:
Applications to targeted contrast agents. Proc IEEE Ultrason Symp 1997; 97CH36118: 16051608.
64.
Lanza GM, Lorenz CH, Fischer SE, Scott MJ, Cacheris WP, Kaufmann RJ, Gaffney PJ,
Wickline SA: Enhanced detection of thrombi with a novel fibrin-targeted magnetic
resonance imaging agent. Acad Radiol 1998; 5: S173-S176.
65.
Hofman MBM, Adzamli K, Allen JS, Fischer SE, Brown JJ, Adams MD, Wickline SA,
Lorenz, CH: Kinetics of a novel blood pool agent (MP-2269) with persistent high relaxivity of
MR angiography. Acad Radiol 1998; 5: S206-S209.
18
66.
Hofman MBM, Wickline SA, Lorenz CH: Quantification of in-plane motion of the coronary
arteries during the cardiac cycle: Implications for acquisition window duration for MR flow
quantification. J Magn Reson Imaging 1998; 8: 568-576.
67.
Lanza GM, Trousil RL, Wallace KD, Rose JH, Hall CS, Scott MJ, Miller JG, Eisenberg PR,
Gaffney PJ, Wickline SA: In vitro characterization of a novel, tissue-targeted ultrasonic
contrast system with acoustic microscopy. J Acoust Soc Am 1998; 104: 3665-3672.
68.
Nagel E, Underwood R, Pennell D, Sechtem UP, Neubauer S, Wickline S, Hess OM,
Schwaiger M, Fleck E: New developments in non-invasive cardiac imaging: Critical
Assessment of the clinical role of cardiac magnetic resonance imaging. Eur Heart J 1998; 19:
1286-1293.
69.
Fischer SE, Wickline SA, de Boer R, Johansson LOM, Lorenz CH: Technical advances
towards a comprehensive cardiac magnetic resonance examination for diagnosis of coronary
artery disease. IEEE Engineering in Medicine and Biology Society 1998; 20: 474-479.
70.
Hall CS, Wickline SA: High frequency ultrasonic detection of protein crosslinking in
myocardial tissue. Proc IEEE Ultrason Symp1998; 98CH36102: 1357-1360.
71.
Hofman MBM, Henson RE, Kovacs SJ, Fischer SE, Lauffer RB, Adzamli K, DeBecker
J, Wickline SA, Lorenz CH: Blood pool agent strongly improves 3D magnetic resonance
coronary angiography using an inversion pre-pulse. Magn Reson Med 1999; 41: 360-367.
72.
Johansson LO, Nolan MM, Taniuchi M, Fischer SE, Wickline SA, Lorenz CH: Highresolution magnetic resonance coronary angiography of the entire heart using a new blood-pool
agent, NC100150 injection: Comparison with invasive x-ray angiography in pigs. J Cardiovasc
Magn Res 1999; 1: 139-143.
73.
Fischer SE, Wickline SA, Lorenz CH: Novel real-time R-wave detection algorithm
based on the vectorcardiogram for accurate gated magnetic resonance acquisitions. Magn
Reson Med 1999; 42: 361-370.
74.
Marsh JN, Hall CS, Abendschein DR, Scherrer DE, Scott MJ, Fuhrhop RJ, Gaffney PJ,
Wickline SA, Lanza GM: Molecular imaging using site-targeted ultrasound contrast agents.
Proc IEEE Ultrason Symp 1999; 99CH37027: 1713-1716.
75.
Hall CS, Scott MJ, Lanza GM, Miller JG, Wickline SA: The extracellular matrix is an
important source of ultrasound backscatter from myocardium. J Acoust Soc Am 2000; 107:
612-619.
76.
Hall CS, Lanza GM, Rose JH, Kaufmann RJ, Fuhrhop RW, Handley SH, Waters KR,
Miller JG, Wickline SA: Experimental determination of phase velocity of perfluorocarbons:
Applications to targeted contrast agents. IEEE Trans Ultrason Ferroelec Freq Contr 2000; 47:
75-84.
19
77.
Lanza GM, Abendschein DR, Hall CS, Marsh JN, Scott MJ, Scherrer DE, Wickline SA:
Molecular imaging of stretch-induced tissue factor expression in carotid arteries with
intravascular ultrasound. Invest Radiol 2000; 35: 227-234.
78.
Flacke S, Setser RM, Barger P, Wickline SA, Lorenz CH: Coronary aneurysms in
Kawasaki’s disease detected by magnetic resonance coronary angiography. Circulation
2000; 101: e156-e157.
79.
Hall CS, Abendschein DR, Scherrer DE, Scott MJ, Marsh JN, Wickline SA, Lanza GM:
Site-targeted acoustic contrast agent detects molecular expression of tissue factor after balloon
angioplasty. Journal of Society of Photo-optical Instrumentation Engineers 2000; 1: 325-332.
80.
Marsh JN, Hall CS, Scott MJ, Fuhrhop RJ, Gaffney PJ, Wickline SA, Lanza GM:
Enhancement of reflectivity by specific perfluorocarbon emulsions used in site-targeted
ultrasound contrast agent. Journal of Society of Photo-optical Instrumentation Engineers 2000;
1: 333-340.
81.
Dent CL, Scott MJ, Wickline SA, Hall CS: High frequency ultrasound for quantitative
characterization of myocardial edema. Ultrasound Med Biol 2000; 26: 375-384.
82.
Hall CS, Nguyen CT, Scott MJ, Lanza GM, Wickline SA: Delineation of the
extracellular determinants of ultrasonic scattering from elastic arteries. Ultrasound Med Biol
2000; 26: 613-620.
83.
Lanza GM, Abendschein DR, Hall CH, Scott MJ, Scherrer DE, Houseman A, Miller JG,
Wickline SA: In vivo molecular imaging of stretch-induced tissue factor in carotid arteries
with ligand-targeted nanoparticles. J Am Soc Echocardiogr 2000; 13: 608-614.
84.
Hall CS, Dent CL, Scott MJ, Wickline SA: High-frequency ultrasound detection of the
temporal evolution of protein cross-linking in myocardial tissue. IEEE Trans Ultrason
Ferroelec Freq Contr 2000; 47: 1051-1058.
85.
Setser R, Henson RE, Allen JS, Fischer SE, Wickline SA, Lorenz CH: Left ventricular
contractility is impaired following myocardial infarction in the pig and rat: Assessment by the
end systolic pressure – volume relation using a single-beat estimation technique and cine
magnetic resonance imaging. Annals of Biomedical Engineering 2000; 28: 484-494.
86.
Anderson SA, Rader RK, Westlin WF, Null C, Jackson D, Lanza GM, Wickline SA,
Kotyk JJ: Magnetic resonance contrast enhancement of neovascular with v3-targeted
nanoparticles. Magn Reson Med 2000; 44: 433-439.
87.
Pohost G, Higgins CB, Grist T, Pettigrew RI, Reichek N, Wickline SA, Axel L,
Manning WJ, Pennell DJ: Guidelines for credentialing in cardiovascular magnetic resonance
(CMR). J Cardiovasc Magn Reson 2000; 2: 233-234.
20
88.
Wickline SA, Fischer KC: Can infections be imaged in implanted devices? ASAIO Journal
2000; 46: S80-S81.
89.
Yu X, Song S-K, Chen J, Scott MJ, Fuhrhop RJ, Hall CS, Gaffney PJ, Wickline SA,
Lanza GM: High resolution MRI characterization of human thrombus using a novel fibrintargeted paramagnetic nanoparticle contrast agent. Magn Reson Med 2000; 44: 867-872.
90.
Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Time evolution of
enhanced ultrasonic reflection using a fibrin-targeted nanoparticle contrast agent. J Acoust Soc
Am 2000; 108: 3049-3057.
91.
Chia JM, Fischer SE, Wickline SA, Lorenz CH: Performance of QRS detection for cardiac
magnetic resonance imaging with a novel vectorcardiographic triggering method J Magn Reson
Imaging 2000; 12: 678-688.
92.
Ferrara KW, Merritt CRB, Burns PN, Foster FS, Mattrey RF, Wickline SA. Evaluation of
tumor angiogenesis with US: Imaging, Doppler, and contrast agents. Acad Radiol 2000; 7:
824-839.
93.
Lanza G, Hall C, Scott M, Fuhrhop R, Marsh J, Wickline S: Molecular imaging with
targeted ultrasound contrast agents. Proc IEEE Ultrason Symp 2000; 00CH37121: 19171926.
94.
Marsh JN, Hall CS, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Time evolution of
enhanced ultrasonic reflection using a fibrin-targeted nanoparticle contrast agent. Proc IEEE
Ultrason Symp 2000; 00CH37121: 1927-1930.
95.
Ngo FC, Hall CS, Marsh JN, Fuhrhop RW, Allen JS, Brown P, McLean MD, Scott MJ,
Wickline SA, Lanza GM: Evaluation of liquid perfluorocarbon nanoparticles as a blood pool
contrast agent utilizing power Doppler harmonic imaging. Proc IEEE Ultrason Symp 2000;
00CH3711: 1931-1934.
96.
Nguyen CT, Hall CS, Scott MJ, Zhu Q, Marsh J, Wickline SA: Age-related alterations
of cardiac tissue microstructure and material properties in Fischer 344 rats. Ultrasound Med
Biol 2001; 27: 611-619.
97.
Hall CS, Marsh JN, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Temperature
dependence of ultrasonic enhancement with a site-targeted contrast agent. J Acoust Soc Am
2001; 110: 1677-1684.
98.
Flacke S, Fischer S, Scott MJ, Fuhrhop RJ, Allen JS, McLean M, Winter P, Sicard GA,
Gaffney PJ, Wickline SA, Lanza GM: Novel MRI contrast agent for molecular imaging of
fibrin: Implications for detecting vulnerable plaques. Circulation 2001; 104: 1280-1285.
21
99.
Dent CL, Bowman AW, Scott MJ, Allen SJ, Lisauskas JB, Janif M, Wickline SA, Kovacs SJ:
Echocardiographic characterization of fundamental mechanisms of abnormal diastolic filling in
diabetic rats with a parameterized diastolic filling formalism. J Am Soc Echocardiogr 2001;
14: 1166-72.
100.
Nagel E, Lorenz C, Baer F, Hundley WG, Wilke N, Neubauer S, Sechtem U, van
der Wall E, Pettigrew R, de Roos A, Fleck E, van Rossum A, Pennell D, Wickline S: Stress
cardiovascular magnetic resonance: Consensus panel report. J Cardiovasc Magn Reson 2001;
3: 267-281.
101.
Handley SM, Ngo F, Hall C, Allen J, McLean M, Lanza G, Miller JG, Wickline SA: Age at
time of infarction differentially affects the remodeling responses in viable cardiac tissue in
young versus old rats. Proc IEEE Ultrason Symp 2001; 01CH37263-2: 1181-1184.
102.
Hughes MS, Marsh JN, Fuhrhop RW, Chinen LK, Lanza GA, Wickline SA: Comparison of
ultrasound scattering properties of Optison® with a liquid perfluorocarbon nanoparticle
contrast agent. Proc IEEE Ultrason Symp 2001; 01CH37263: 1675-1678.
103.
Takiuchi S, Marsh JN, Hall CS, Lanza GM, Wickline SA: Unexpected anisotropic
behavior of ultrasound attenuation after collagen cross-linking in porcine tendons. Proc IEEE
Ultrason Symp 2001; 01CH37263: 1253-1256.
104.
Marsh JN, Hall CS, Scott MJ, Fuhrhop RJ, Gaffney PJ, Wickline SA, Lanza GM:
Improvements in the ultrasonic contrast of targeted perfluorocarbon nanoparticles using an
acoustic transmission line model. IEEE Trans Ultrason Ferroelec Freq Contr 2002; 49: 29-38.
105.
Wickline SA, Sahn DJ, Kerber R, Reichek N, Pennell DJ: Report from the First
International Conjoint Conference on Cardiovascular Magnetic Resonance and
Echocardiography. J Cardiovasc Magn Res 2002; 4: 515-520.
106.
Nguyen CT, Hall CS, Wickline SA: Characterization of aortic microstructure with highfrequency ultrasound: implications for mechanisms of aortic function and dissection. IEEE
Trans Ultrason Ferroelec Freq Contr 2002; 49: 1561-1571.
107.
Lanza GM, Yu X, Winter PM, Abendschein DR, Karukstis KK, Scott MJ, Chinen, LK,
Fuhrhop RW, Scherrer DE, Wickline SA: Targeted antiproliferative drug delivery to vascular
smooth muscle cells with magnetic resonance imaging nanoparticle contrast agent:
implications for rational therapy of restenosis. Circulation 2002; 106: 2842-2847.
108.
Lanza GM, Abendschein DR, Yu X, Winter PM, Karukstis K, Scott MJ, Fuhrhop RW,
Scherrer DE, Wickline SA: Molecular imaging and targeted drug delivery with a novel,
ligand-directed paramagnetic nanoparticle technology. Acad Radiol 2002; 9: S330-S331.
22
109.
Wickline SA, Hughes M, Ngo FC, Hall CS, Marsh JN, Brown PA, Allen JS, McLean MD,
Scott MJ, Fuhrhop RW, Lanza GM: Blood contrast enhancement with a novel, non-gaseous
nanoparticle contrast agent. Acad Radiol 2002; 9: S290-S293.
110.
Marsh JN, Hall CS, Wickline SA, Lanza GM: Temperature dependence of acoustic
impedance for specific fluorocarbon liquids. J Acoust Soc Am 2002; 112: 2858-2862.
111.
Hughes MS, Marsh JN, Woodson AK, Fuhrhop RW, Lanza GM, Wickline SA:
Comparison of ultrasound scattering behavior of Optison® and a liquid perflourocarbon
nanoparticle contrast agent. Proceedings of IEEE Ultrason Ferroelec Freq Contr 2002;
02CH37388-2: 1965-1968.
112.
Wickline SA, Lanza GM: Nanotechnology for molecular imaging and targeted therapy.
Circulation 2003; 107: 1092-1095.
113.
Handley SM, Ngo F, McLean M, Hall CS, Allen J, Crowder K, Miller JG, Lin SJ, Hughes
MS. Wickline SA. Chronological age modifies the microscopic remodeling process in viable
cardiac tissue after infarction. Ultrasound Med Biol 2003; 29(5): 659-69.
114.
Winter PM, Caruthers SD, Yu X, Song SK, Chen JJ, Miller B, Bulte JWM,
Robertson JD, Gaffney PJ, Wickline SA, Lanza GM. Improved Molecular Imaging
Contrast Agent for Detection of Human Thrombus. Magn Reson Med 2003; 50: 411-416.
115.
Chen JJ, Song SK, Liu W, McLean M, Allen JS, Tan J, Wickline SA, Yu X: Remodeling of
cardiac fiber structure after infarction in rats quantified with diffusion tensor MRI. Am J
Physiol Heart Circ Physiol 2003; 285: H946-H954.
116.
Handley SM, Ngo F, McLean M, Hall CS, Allen J, Crowder K, Miller JG, Lin SJ, Hughes
MS, Wickline SA: Chronological age modifies the microscopic remodeling process in viable
cardiac tissue after infarction. Ultrasound Med Biol 2003; 29: 659-669.
117.
Winter PM, Caruthers SD, Kassner A, Harris TD, Chinen LK, Allen JS, Lacy EK, Zhang HY,
Robertson JD, Wickline SA, Lanza GM: Molecular imaging of angiogenesis in nascent Vx-2
rabbit tumors using a novel v3-targeted nanoparticle and 1.5 Tesla magnetic resonance
imaging. Cancer Research 2003; 63: 5838-5843.
118.
Caruthers SD, Lin R, Brown P, Watkins MP, Williams TA, Lehr KA, Wickline SA:
Practical value of cardiac magnetic resonance imaging for clinical quantification of aortic valve
stenosis. Comparison with echocardiography. Circulation 2003; 108: 2236-2243.
119.
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams TA, Allen JS,
Lacy EK, Robertson JD, Lanza GM, Wickline SA: Molecular imaging of angiogenesis in earlystage atherosclerosis with v3-integrin-targeted nanoparticles. Circulation 2003; 108: 22702274.
23
120.
Buxton DB, Lee SC, Wickline SA, Ferrari M: Recommendations of the National Heart,
Lung, and Blood Institute Nanotechnology Working Group. Buxton: NHLBI Nanotechnology
Working Group. Circulation 2003; 108: 2737-2742.
121.
Lanza GM, Wickline SA: Targeted ultrasonic contrast agents for molecular imaging and
therapy. Curr Prob Cardiology 2003; 28: 625-653.
122.
Lanza GM, Winter PM, Caruthers SD, Hughes MS, Hall CS, Marsh JN, Scott MJ, Zhang
H, Schmieder A, Crowder K, Morawski A, Wickline SA: Molecular imaging and targeted drug
delivery: Merging medical paradigms. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 526531.
123.
Hughes MS, Marsh JN, Hall CS, Fuhrhop RW, Lanza GM, Wickline SA: Optimization of
site-targeted perfluorocarbon nanoparticle contrast in whole blood for molecular imaging
applications. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 536-535.
124.
Crowder KC, Hughes MS, Marsh JN, Scott MJ, Fuhrhop RW, Lanza GM, Wickline SA:
Augmented and selective delivery of liquid perfluorocarbon nanoparticles to melanoma cells
with noncavitational ultrasound. Proc IEEE Ultrason Symp 2003; 03CH37476-1: 532-535.
125.
Morawski AM, Winter PM, Caruthers SD, Williams TA, Allen JS, Fuhrhop RW,
Lanza GM, Wickline SA: A semi-automated algorithm for quantification of vessel wall
angiogenesis associated with early atherosclerosis using magnetic resonance imaging. Proc
IEEE-EMBS 2003; 03CH37439-1: 743-746.
126.
Morawski AM, Winter PM, Crowder KC, Caruthers SD, Fuhrhop RW, Scott MJ,
Robertson JD, Abendschein DR, Lanza GM. Wickline SA: Targeted nanoparticles
for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med 2004; 51:
480-486.
127.
Rogers JH, Caruthers SD, Williams T, Lin SJ, Meyers D, Lanza GM, Kovacs S, Lasala
JM, Wickline SA. Clinical utility of rapid prescreening magnetic resonance angiography of
peripheral vascular disease prior to cardiac catheterization. J Cardiovasc Magn Reson 2004; 6:
25-31.
128.
Wickline SA: Plaque characterization: Surrogate markers or the real thing? J Am Coll Cardiol
2004; 43: 1185-1187.
129.
Marsh JN, Takiuchi S, Lin SJ, Lanza GM, Wickline SA: Ultrasonic delineation of aortic
microstructure: The relative contribution of elastin and collagen to aortic elasticity. J Acoust
Soc Am 2004; 115: 2032-2040.
130.
Lin SJ, Brown PA, Watkins MP, Williams TA, Lehr KA, Liu W, Lanza GM, Wickline SA,
Caruthers SD: Quantification of stenotic mitral valve area with magnetic resonance
imaging and comparison with Doppler ultrasound. J Am Coll Cardiol 2004; 44: 133-137.
24
131.
Liu W, Chen J, Ji S, Allen JS, Bayly PV, Wickline SA, Yu X: Harmonic phase MR tagging for
direct quantification of Lagrangian strain in rat hearts after myocardial infarction. Magn Reson
Med 2004; 52: 1282-1290.
132.
Morawski AM, Winter PM, Yu X, Fuhrhop RW, Scott MJ, Hockett F, Robertson JD, Gaffney
PJ, Lanza GM, Wickline SA: Quantitative "magnetic resonance immunohistochemistry" with
ligand-targeted 19F Nanoparticles. Magn Reson Med 2004; 52: 1255-1262.
133.
Lanza GM, Winter PM, Caruthers SD, Morawski AM, Schmieder AH, Crowder KC, Wickline
SA: Magnetic resonance molecular imaging with nanoparticles: From bench to bedside. J
Nuclear Cardiol 2004; 11: 733-743.
134.
Gaynor SL, Ishii Y, Diodato MD, Prasad SM, Barnett KM, Damiano NR, Byrd GD, Wickline
SA, Schuessler RB, Damiano RJ: Successful performance of Cox-Maze procedure on beating
heart using biopolar radiofrequency ablation: A feasibility study in animals. Ann Thorac Surg
2004; 78: 1671-1677.
135.
Mokadam NA, McCarthy PM, Gillinov AM, Ryan WH, Moon MR, Mack MJ, Gaynor SL,
Prasad SM, Wickline SA, Bailey MS, Damiano NR, Ishii Y, Schuessler RB, Damiano RJ: A
prospective multicenter trial of bipolar radiofrequency ablation for atrial fibrillation: Early
results. Ann Thorac Surg 2004; 78: 1665-1670.
136.
Lanza GM, Winter P, Caruthers S, Schmieder AH, Crowder K, Morawski A, Zhang H, Scott
MJ, Wickline SA: Novel paramagnetic contrast agents for molecular imaging and targeted
drug delivery. Curr Pharm Biotechnol 2004; 5: 495-507.
137.
Marsh JN, Crowder KC, Hughes MS, Scott MJ, Lacy EK, Lanza GM, Wickline SA: In vitro
acoustic molecular imaging of tissue factor expressed by smooth muscle cells with stable liquid
perfluorocarbon nanoparticle contrast agents. IEEE Ultrason Symp 2004; 04CH37553-2: 11021105.
138.
Hughes MS, Marsh JN, Allen J, Brown PA, Lacy EK, Scott MJ, Lanza GM, Wickline SA, Hall
CS: In vivo ultrasonic detection of angiogenesis with site-targeted nanoparticle contrast agents
using measure-theoretic signal receivers. IEEE Ultrason Symp 2004; 04CH37553-2: 11061109.
139.
Schmieder AH, Winter PM, Caruthers SD, Harris TD, Williams TA, Allen JS, Lacy EK,
Zhang H, Scott MJ, Hu G, Robertson JD, Wickline SA, Lanza GM: Molecular MR imaging of
melanoma angiogenesis with v3-Targeted paramagnetic nanoparticles. Magn Reson Med
2005; 53: 621-627.
140.
Hughes MS, Marsh JN, Hal CS, Savery D, Lanza GM, Wickline SA: Characterization of
digital waveforms using thermodynamic analogs: Applications to detection of materials defects.
IEEE Trans Ultrason Ferroelec Freq Contr 2005; 52: 1555-1564.
25
141.
Robertson JD, Crane SB, Wickline SA, Lanza GM: Characterization and biodistribution of a
novel MRI molecular imaging agent by neutron activation analysis. Journal of Radioanalytical
and Nuclear Chemistry 2005; 263: 511-514.
142.
Winter P, Athey P, Kiefer G, Gulyas G, Frank K, Fuhrhop R, Robertson D, Wickline S, Lanza
GM: Improved paramagnetic chelate for molecular imaging with MRI. Journal of Magnetism
and Magnetic Materials 2005; 293: 540-545.
143.
Hughes MS, Marsh JN, Hall CS, Fuhrhop RW, Lacy EK, Lanza GM, Wickline SA:
Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound
contrast agent for molecular imaging. J Acoust Soc Am 2005; 117: 964-972.
144.
Cyrus T, Winter PW, Caruthers SD, Wickline SA, Lanza GM: Magnetic resonance
nanoparticles for cardiovascular molecular imaging and therapy. Expert Rev Cardiovasc Ther
2005; 3(4): 705-715.
145.
Winter PM, Shukla HP, Caruthers SD, Scott MJ, Fuhrhop RW, Robertson JD, Gaffney PJ,
Wickline S, Lanza GM: Molecular imaging of human thrombus with computed tomography.
Acad Radiol 2005; 12 (Suppl 1): 9-13.
146.
Waters EA, Caruthers SD, Wickline SA: Correlation analysis of stenotic aortic valve flow
patterns using phase contrast MRI. Ann Biomed Eng 2005; 33(7): 878-887.
147.
Lanza GM, Hughes MS, Marsh JN, Scott MJ, Zhang H, Lacy EK, Allen JS, Wickline SA:
Acoustic molecular imaging and targeted drug delivery with perfluorocarbon nanoparticles.
AIP Conf Proc 2005; 754: 120-123.
148.
Hughes MS, Marsh JN, Woodson AJ, Lacy EK, Caradine C, Lanza GM, Wickline SA:
Characterization of digital waveforms using thermodynamic analogs: Detection of contrast
targeted tissue in MDA 435 tumors implanted in athymic mice. Proc IEEE Ultrason Symp
2005; 05CH37716-1: 373-376.
149.
Chen J, Liu W, Zhang H, Lacy L, Yang X, Song SK, Wickline SA, Yu X: Regional ventricular
Wall thickening reflects changes in cardiac fiber and sheet structure during contraction:
quantification with diffusion tensor MRI. Am J Physiol Heart Circ Physiol 2005; 289: H18981907.
150.
Ashford MW, Liu W, Lin SJ, Abraszewski P, Caruthers SD, Connolly AM, Yu X, Wickline
SA: Occult cardiac contractile dysfunction in dystrophin-deficient children revealed by cardiac
magnetic resonance strain imaging. Circulation 2005; 112 (16): 2462-2467.
151.
Wickline SA, Lanza GM: Targeted nanoparticle beacons for quantification of molecular
epitopes and drug delivery. Clinical Cancer Research 2005; 11: 9173S-9174S.
26
152.
Crowder KC, Hughes MS, Marsh JN, Barbieri AM, Fuhrhop RW, Lanza GM, Wickline SA:
sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid
delivery to cancer cells through contact-mediated mechanisms: Implications for enhanced
local drug delivery. Ultrasound Med Biol 2005; 31 (12): 1693-1700.
153.
Hughes MS, Marsh JN, Arbeit J, Neumann R, Fuhrhop RW, Lanza, GM, Wickline SA.:
Ultrasonic molecular imaging of primordial angiogenic vessels in rabbit and mouse models
with avb3-integrin targeted nanoparticles using information-theoretic signal detection: Results
at high frequency and in the clinical diagnostic frequency range. Proc IEEE Ultrason Symp
2005; 05CH37716-1: 617-620.
154.
Marsh JN, Pan A, Hu G, Crowder KC, Scott MJ, Hughes MS, Wickline SA, Lanza GM:
Fibrin-targeted thrombolytic therapy using acoustically reflective perfluorocarbon
nanoparticles. Proc IEEE Ultrason Symp 2005; 05CH37716-2: 992-995.
155.
Soman NR, Marsh JN, Hughes MS, Lanza GM, Wickline SA: Noncavitational mechanisms of
interaction of targeted perfluorocarbon nanoparticles: Implications for drug delivery. Proc
IEEE Ultrason Symp 2005; 05CH37716-3: 1712-1715.
156.
Cyrus T, Abendschein DR, Caruthers SD, Harris TD, Glattauer V, Werkmeister JA, Ramshaw
JA, Wickline SA, Lanza, G.M: MR three-dimensional molecular imaging of intramural
biomarkers with targeted nanoparticles. J Cardiovasc Magn Reson 2006; 8: 535-541.
157.
Caruthers SD, Neubauer AM, Hockett FD, Lamerichs R, Winter PM, Scott MJ, Gaffney PJ,
Wickline SA, Lanza GM. In vitro demonstration using 19F magnetic resonance to augment
molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol
2006; 41: 305-312.
158.
Chung J, Abraszewski P, Yu X, Liu W, Krainik A, Ashford M, Caruthers SD, McGill JB,
Wickline SA: Paradoxical increase in ventricular torsion and systolic torsion rate in Type I
diabetic patients under tight glycemic control. J Am Coll Cardiol 2006; 47: 384-390.
159.
Soman NR, Marsh, JN, Hughes MS, Lanza GM, Wickline SA: Acoustic activation of targeted
liquid perfluorocarbon nanoparticles does not compromise endothelial integrity. IEEE Trans
NanoBioscience 2006; 5: 69-75.
160.
Winter PM, Caruthers SD, Wickline SA, Lanza GM: Molecular imaging by MRI. Curr
Cardiol Rep 2006; 8: 65-69.
161.
Wickline SA, Lanza GM: Nanotechnology for molecular imaging and targeted drug delivery.
Annals of Oncology 2006; 17: 30.
162.
Wickline SA, Neubauer AM, Winter P, Caruthers S, Lanza G: Applications of nanotechnology
to atherosclerosis, thrombosis, and vascular biology. Arterioscler Thromb Vasc Biol 2006; 26:
435-441.
27
163.
Hughes M, Marsh JN, Zhang H, Woodson AK, Allen JS, Lacy EK, Caradine C, Lanza GM,
Wickline SA: Characterization of digital waveforms using thermodynamic analogs: Detection
of contrast-targeted tissue in vivo. IEEE Trans Ultrason Ferroelectr Freq Contr 2006; 53:
1609-1616.
164.
Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder
AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM: Endothelial avb3 integrintargeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler Thromb
Vasc Biol 2006; 26: 2103-2109.
165.
Liu W, Ashford MW, Chen J, Watkins MP, Williams TA, Wickline SA, Yu X: MR tagging
demonstrates quantitative differences in regional ventricular wall motion in mice, rats, and men.
Am J Physiol Heart Circ Physiol 2006; 291: H2515-2521.
166.
Winter PM, Cai K, Chen J, Adair CR, Kiefer GE, Athey PS, Gaffney PJ, Buff CE, Robertson
JD, Caruthers SD, Wickline SA, Lanza GM: Targeted PARACEST nanoparticle contrast agent
for the detection of fibrin. Magn Reson Med 2006; 56: 1384-1388.
167.
Lanza GM, Winter P, Cyrus T, Caruthers S, Marsh J, Hughes M, Wickline S: Nanomedicine
opportunities in cardiology. Ann N Y Acad Sci 2006; 1080: 451-465.
168.
Lanza GM, Winter PM, Caruthers SD, Hughes MS, Cyrus T, Marsh JN, Neubauer AM, Partlow
KC, Wickline SA: Nanomedicine opportunities for cardiovascular disease with
perfluorocarbon nanoparticles. Nanomedicine 2006; 1: 321-329.
169.
Caruthers SD, Wickline SA, Lanza GM: Nanotechnological applications in medicine. Curr
Opin Biotechnol 2007; 18: 26-30.
170.
Neubauer AM, Caruthers SD, Hockett FD, Cyrus T, Robertson JD, Allen JS, Williams TD,
Fuhrhop RW, Lanza GM, Wickline SA: Fluorine cardiovascular magnetic resonance
angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J Cardiovasc
Magn Reson 2007; 9: 565-573.
171.
Hu G, Lijowski M, Zhang H, Partlow KC, Caruthers SD, Kiefer G, Gulyas G, Athey P, Scott
MJ, Wickline SA, Lanza GM: Imaging of Vx-2 rabbit tumors with alpha(nu)beta(3)-integrin
targeted 111In nanoparticles. Int J Cancer 2007; 120: 1951-1957.
172.
Marsh JN, Partlow KC, Abendschein DR, Scott MJ, Lanza GM, Wickline SA: Molecular
imaging with targeted perfluorocarbon nanoparticles: Quantification of the concentration
dependence of contrast enhancement for binding to sparse cellular epitopes. Ultrasound Med
Biol 2007; 33: 950-958.
28
173.
Hughes MS, Marsh JN, Wallace KD, Donahue TA, Connolly AM, Lanza GM, Wickline SA:
Sensitive ultrasonic detection of dystrophic skeletal muscle in patients with Duchenne muscular
dystrophy using an entropy-based signal receiver. Ultrasound Med Biol 2007; 33: 1236-1243.
174.
Hughes MS, McCarthy JE, Marsh JN, Arbeit JM, Neumann RG, Fuhrhop RW, Wallace KD,
Znidersic DR, Maurizi BN, Baldwin SL, Lanza GM, Wickline SA: Properties of an Entropybased Signal Receiver with an Application to Ultrasonic Molecular Imaging. J Acous Soc Am
2007; 121: 3542-3557.
175.
Partlow KC, Chen J, Brant JA, Neubauer AM, Meyerrose TE, Creer MH, Nolta JA, Caruthers
SD, Lanza GM, Wickline SA: 19F magnetic resonance imaging for stem/progenitor cell
tracking with multiple unique perfluorocarbon nanobeacons. FASEB J 2007; 21: 1647-1654.
176.
Marsh JN, Senpan A, Hu G, Scott MJ, Gaffney PJ, Wickline SA, Lanza GM: Fibrin-targeted
perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2007; 2: 533-543.
177.
Ripplinger CM, Li W, Hadley J, Chen J, Rothenberg F, Lombardi R, Wickline SA, Marian AJ,
Efimov IR: Enhanced transmural fiber rotation and connexin 43 heterogeneity are associated
with an increased upper limit of vulnerability in a transgenic rabbit model of human
hypertrophic cardiomyopathy. Circ Res 2007; 101: 1049-1057.
178.
Wallace KD, Marsh JN, Baldwin SL, Connolly AM, Keeling R, Lanza GM, Wickline SA,
Hughes MS: Sensitive Ultrasonic Delineation of Steroid Treatment in Living Dystrophic Mice
with Energy-based and Entropy-based Radio Frequency Signal Processing. IEEE Trans
Ultrason Ferroelectr Freq Control 2007; 54: 2291-2299.
179.
Tran TD, Caruthers SD, Hughes M, Cyrus T, Winter PM, Morawski AN, Wickline SA, Lanza
GM: Clinical applications of perfluorocarbon nanoparticles for molecular imaging and targeted
therapeutics. Int J Nanomedicine 2007; 2: 515-526.
180.
Cyrus T, Allen JS, Williams TA, Fuhrhop RW, Harris TD, Glattauer V, Werkmeister J,
Ramshaw J, Wickline SA, Lanza GM: Intramural delivery of rapamycin with avb3-integrintargeted paramagnetic nanoparticles inhibits stenosis following angioplasty. Arterioscler
Thromb Vasc Biol (In press)
181.
Hughes M, Caruthers S, Tran T, Marsh J, Wallace K, Cyrus T, Partlow KP, Scott M, Lijowski
M, Neubauer A, Winter P, Hu G, Zhang H, McCarthy J, Maurizi B, Allen J, Caradine C,
Neumann R, Arbeit J, Lanza G, Wickline S: Perfluorocarbon nanoparticles for molecular
imaging and targeted therapeutics. Proceedings of the IEEE 2008; 96: _____ (In press)
182.
Chen J, Wang Q, Zhang H, Yang X, Wang J, Berkowitz BA, Wickline SA, Song SK: In vivo
quantification of T1, T2, and appartent diffusion coefficient in the mouse retina at 11.74. Magn
Res Med (Accepted)
29
183.
Soman N, Marsh J, Hughes M, Lanza G, Wickline S: New mechanisms for nonporative
ultrasound stimulation of cargo delivery to cell cytosol with targeted perfluorocarbon
nanoparticles. Nanotechnology (Accepted)
184.
Winter PM, Morawski AM, Caruthers SD, Fuhrhop RW, Zhang H, Williams T, Allen JS,
Harris TD, Wickline SA, Lanza GM. Antiangiogenic therapy of early-stage atherosclerosis
with avb3-integrin-targeted fumagillin nanoparticles. ATVB (In review)
185.
Partlow KC, Lanza GM, Wickline SA: Lipid-drug delivery from molecularly targeted
nanoparticles utilizes caveolar lipid raft transport mechanisms. FASEB J (In review)
186.
Waters EA, Chen J, Allen JS, Lanza GM, Wickline SA: Detection and quantification of
angiogenesis in experimental valve disease with integrin-targeted nanoparticles and 19-fluorine
MRI/MRS. J Cardiovasc Magn Reson (In review)
187.
Neubauer M, Caruthers SD, Hockett FD, Winter PM, Chen J, Gaffney PJ, Robertson JD, Lanza
GM, Wickline SA: Tunable perfluorocarbon nanoparticles for molecular imaging using
gadolinium-modulated 19F signals. Magn Res Med (In review)
188.
Partlow KC, Brant JA, Marsh JN, Creer MH, Nolta JA, Hughes MS, Lanza GM, Wickline SA:
Extraordinary acceleration of endocytosis with acoustic energy: Mechanisms and practical
applications. Nature Biotechnology (In review)
189.
Partlow KC, Lanza GM, Wickline SA: Exploiting lipid raft transport with targeted
nanoparticles: A strategy for cytosolic drug delivery. Biomaterials (In review)
190.
Neubauer AM, Caruthers SD, Brant J, Partlow KC, Lanza GM, Wickline SA: 19F MRI at 3.0
T: Sensitivity and detection limits for molecular imaging and cell labeling. Magn Res Med (In
review)
191.
Myerson JW, Chen J, Yang X, Neubauer AM, Lanza GM, Wickline SA: A novel real time
approach for in vivo pharmacokinetic modeling of perfluorocarbon nanoparticles employing
quantitative 19F magnetic resonance spectroscopy. Magn Res Med (In revision)
192.
Neubauer AM, Sim H, Winter PW, Caruthers SD, Williams TA, Robertson JD, Sept D, Lanza
GM, Wickline SA: Novel nanoparticle pharmacokinetic profiling based on in vivo magnetic
resonance imaging. J Magn Res Imaging (In review)
193.
Chen J, Waters EA, Yang X, Zhang H, Neumann R, Arbeit J, Lanza GM, Wickline SA:
Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR
specroscopy. J Magn Res Imaging (In review)
194.
Southworth R, Kaneda M, Chen J, Zhang L, Zhang H, Yang X, Razavi R, Lanza G, Wickline
S: Renal vascular inflammation induced by western diet in ApoE-null mice quantified by 19F
NMR of VCAM-1 targeted nanobeacons. Circ Res (In review)
30
195.
Soman NR, Lanza GM, Wickline SA, Schlesinger PH: Targeting cytotoxic cell penetrating
peptides (Melittin) with self-assembling nanoemulsions. Cell (In review)
196.
Soman NR, Lanza GM, Wickline SA, Schlesinger PH: Synthesis and characterization of
perfluorocarbon nanodroplets as drug delivery vehicles for cytolytic peptides. Nanoletters (In
review)
197.
Kaneda M, Lanza GM, Milbrant J, Wickline SA: siRNA delivery with PFC nanoparticles:
Downregulation of vascular adhesion molecules (In preparation)
Invited Publications/Book Chapters/Reviews
1.
Soeter JR, Wickline SA, McNamara JJ: Carotid and aortic root perfusion during venoarterial
bypass in primates. In: Artificial Lungs for Acute Respiratory Failure. Warren Zapol and Jasper
Quist, editors. Academic Press, NY. Hemisphere Publishing Corp., Washington, D.C., 1976,
pp 275-81.
2.
Fields LE, Wickline SA: Hypertension. Chapter 4 in: Manual of Medical Therapeutics (25th
edition). Department of Medicine, Washington University School of Medicine, St. Louis,
Missouri. Matthew Orland, M.D. and Robert Saltman, M.D., editors. Little, Brown and
Company, Boston, 1986.
3.
Perez JE, Miller JG, Barzilai B, Wickline SA, Mohr GA, Wear K, Vered Z, Sobel BE:
Progress in quantitative ultrasonic characterization of myocardium: from the laboratory to the
bedside. J Am Society of Echocardiography 4: 294, 1988.
4.
Perez JE, Barzilai B, Wickline SA, Vered Z, Sobel BE, Miller JG: Quantitative
characterization of myocardium with ultrasonic imaging. J Nuc Med Allied Sci 32: 149, 1988.
5.
Wickline SA, Perez JE, Mohr GA, Wear KA, Milunski MR, Barzilai B, Sobel BE,
Miller JG: Ultrasonic characterization of cardiovascular tissue. In: Proceedings of NIH
Conference on Modeling in Biomedical Research: An Assessment of Current and Potential
Approaches, Applications to Studies in Cardiovascular/Pulmonary Function and Diabetes.
May 1-3, 1989.
6.
Perez JE, Wickline SA, Barzilai B, Loomis JS, Waggoner A, Miller JG: Ultrasonic integrated
backscatter imaging. Dynamic Cardiovascular Imaging 2: 87-91, 1989.
7.
Miller JG, Barzilai B, Milunski MR, Mohr GA, Perez JE, Wear KA, Wickline SA, Vered Z,
Sobel BE: Myocardial tissue characterization: Clinical confirmation of laboratory results. IEEE
Ultrason Symp 89CH2791-2: 1029-36, 1989.
8.
Wickline SA, Sobel BE: Ultrasonic tissue characterization: Prospects for clinical
investigation. J Am Coll Cardiol 14: 1709, 1989.
31
9.
Perez JE, Miller JG, Wickline SA, Milunski MR, Barzilai B, Sobel BE: Myocardial tissue
characterization. Progress in Cardiology 3(1): 83-96, 1990.
10.
Perez JE, Miller JG, Wickline SA, Barzilai B, Sobel BE: Assessment of myocardial viability
with analysis of ultrasonic integrated backscatter. Proc 12th International Conference of IEEE
Engineering Med Biol Society 12: 325-326, 1990.
11.
Skorton DJ, Miller JG, Wickline SA, Barzilai B, Collins SM, Perez JE: Ultrasonic
characterization of cardiac tissue. Chapter 26 in: Cardiac Imaging-Principles and Practice.
Marcus ML, Schelbert HR, Skorton DJ, Wolf G, editors. WB Saunders, Co., Philadelphia PA.
1991, 538-556.
12.
Wickline SA, Perez JE, Miller JG: Chapter 10: Cardiovascular tissue characterization in vivo,
in: Shung KK and GA Thieme (ed). Ultrasonic Scattering In Biological Tissues. Boca Raton,
FL, CRC Press, 1993, 313-345.
13.
Perez, JE, Miller JG, Holland MR, Wickline SA, Waggoner AD, Barzilai B, Sobel BE:
Ultrasonic tissue characterization: Integrated backscatter imaging for detecting myocardial
structural properties and on-line quantification of cardiac function. Am J Cardiac Imaging
8: 106-112, 1994.
14.
Wickline SA: Quantitative Ultrasonic Imaging. Chapter 23 in Vascular Surgery: Theory and
Practice. Callow AD & CB Ernest, editors. Appleton & Lange, Stamford, CT. 1995, 331-334.
15.
Lanza GM, Wallace KD, Miller JG, Wickline SA: Development of a Novel Site Targeted
Ultrasonic Contrast Agent. In: Advances in Echo Imaging Using Contrast Enhancement.
Nanda NC, Schlief R, Goldberg BB, editors. Kluwer Academic Publishers, Norwell, MA.
1997, 655-667.
16.
Wickline SA, Miller JG, Lanza G: Quantitative ultrasonic tissue characterization with
intravascular and transcutaneous ultrasound. In: Non-invasive Imaging of Atherosclerosis. M.
Mercuri, D.D. McPherson, H. Bassiouny, S. Glagov, editors. Kluwer Academic Publishers,
Norwell, MA. 1998, 169-188.
17.
Wickline S, Wu K, Didisheim P, Anderson JM, Budinger TF, Fuster V, Harker LA,
Kottke-Marchant K, Maki DG, Strauss W, Callahan TH, Watson JT, Berson A: NHLBI/FDA
conference on thrombosis and infections with cardiovascular devices. J Biomed Mater Res 42:
341-346, 1998.
18.
Holland MR, Perez JE, Wickline SA, Handley SM, Finch-Johnston AE, Mobley J, Hall
CS, Wallace KD, Miller JG: Clinical implementation of ultrasonic quantitative nondestructive
evaluation of the heart: A review. Nondestr Test Eval 14: 217-235, 1998.
32
19.
Nagel E, Underwood R, Pennell D, Sechtem UP, Neubauer S, Wickline S, Hes OM,
Schwaiger M, Fleck E: Recent developments in non-invasive heart imaging. Critical evaluation
of the use of cardiac magnetic resonance tomography – results of an interdisciplinary workshop.
Dtsch Med Wochenschr 123: 1018-1021, 1998.
20.
Budinger TF, Berson A, McVeigh ER, Pettigrew RI, Pohost GM, Watson JT, Wickline
SA: Cardiac MR imaging: Report of a working group sponsored by the National Heart, Lung,
and Blood Institute. Radiology 208: 573-576, 1998.
21.
Miller JG, Perez JE, Wickline SA, Baldwin SL, Barzilai B, Davila-Roman V, Fedewa
RJ, Finch-Johnston AE, Hall CS, Handley SM, Hockett FD, Holland MR, Kovacs A, Lanza
GM, Lewis SS, Marsh JN, Mobley J, Sosnovik DE, Trousil RL, Wallace KD, Waters KR:
Backscatter Imaging and myocardial tissue characterization. Proc IEEE Ultrason Symp
98CH36102: 1373-1379, 1998.
22.
Budinger T, Berson A, McVeigh E, Pettigrew R, Pohost G, Watson J, Wickline S:
NHLBI Working Group on Cardiovascular Magnetic Resonance: Magnetic Resonance Imaging
of the Cardiovascular System. J Cardiovasc Magn Reson 1: 53-58, 1999.
23.
Lanza GM, Wickline SA. Targeted ultrasonic contrast agents for molecular imaging and
therapy. In: Progress in Cardiovascular Diseases. M. Lesch and E.H. Sonneblick, editors.
W.B. Saunders, Philadelphia, PA. 2000, 13-31.
24.
Holland MR, Wickline SA: Ultrasonic Characterization of Myocardium. In: Interstitial
Fibrosis in Heart Failure. F. Villa real, editor. Kluwer Academic Publishers, Norwell, MA.
25.
Wickline SA, Lanza GM: Molecular imaging, targeted therapeutics, and nanoscience. J
Cellular Biochemistry 87 (Suppl 39): 90-97, 2002.
26.
Lanza GM, Lamerichs R, Caruthers S, Wickline SA: Molecular imaging in MR with a
targeted paramagnetic nanoparticles. Medica Mundi 47: 34-39, 2003.
27.
Hughes MS, Lanza GM, Marsh JN, Wickline SA: Targeted Ultrasonic Contrast Agents
for Molecular Imaging and Therapy: A Brief Review. Medica Mundi 47: 66-73, 2003.
28.
Lanza GM, Caruthers SD, Wickline SA: Molecular Imaging. In: Cardiovascular Magnetic
Resonance, ed Lardo, Fayad, Chronos and Fuster. Taylor and Francis Group 2004; 501-516.
29.
Morawski AM, Lanza GM, Wickline SA. Targeted contrast agents for magnetic resonance
imaging and ultrasound. Curr Opin Biotechnol 2005; 16: 89-92.
30.
Lanza GM, Winter PM, Neubauer AM, Caruthers SD, Hockett F, Wickline SA: 1H/19F
magnetic resonance molecular imaging with perfluorocarbon nanoparticles. In: Current Topics
in Developmental Biology: In Vivo Cellular and Molecular Imaging. Eric T. Ahrens, editor.
2005; 70: 57-76.
33
31.
Winter PM, Caruthers SD, Wickline SA, Lanza GM: Nanotechnologies for cellular and
molecular imaging by MRI: Techniques, Tools, Applications, and Impact. In: Nanofabrication
Towards Biomedical Applications. CSSR Kumar, J Hormes, C Leuschner (Eds.) Wiley-VCH
Verlag GmbH & Co. KGaA, Weinheim, 2005; 227-249.
32.
Caruthers S, Winter P, Wickline SA, Lanza GM. "Targeted Magnetic Resonance Imaging
Contrast Agents”. In: Magnetic Resonance Imaging: Methods Mol Med 2006; 124: 387-400.
33.
Lanza GM, Winter PM, Hughes MS, Caruthers SD, Marsh JN, Morawski AM, Schmieder AH,
Scott MJ, Fuhrhop RW, Zhang H, Hu G, Lacy EK, Allen JS, Wickline SA. Molecular imaging
and therapy: New paradigms for 21st century medicine. In: Polymeric Drug Delivery I:
Particulate Drug Carriers. Sonke Svenson, editor. American Chemical Society Symposium
Series 2006; 923: 295-311.
34.
Caruthers SD, Wickline SA, Lanza GM: Targeted Nanoparticles for Molecular Imaging and
Therapy. Chapter 19. In: Advances in Healthcare Technology: Shaping the Future of Medical
Care. Gerhard Spekowius, Thomas Wendler Editors. Springer, 2006, 305-322.
35.
Cyrus T, Winter PM, Caruthers SD, Wickline SA, Lanza GM: Nanoparticles for magnetic
resonance imaging of tumors. In: Nanomaterials for Cancer Therapy and Diagnosis (Series:
Nanotechnologies for Life Sciences, Volume 6). Editor: Challa S.S.R. Kumar. Wiley-VCH
Verlag GmbH, 2007; 121-146.
36.
Winter PM, Cai K, Caruthers SD, Wickline SA, Lanza GM: Emerging nanomedcine
opportunities with perfluorocarbon nanoparticles. Expert Rev Med Devices 2007; 4: 137-145.
37.
Wickline SA, Neubauer AM, Winter PM, Caruthers SD, Lanza GM: Molecular imaging and
therapy of atherosclerosis with targeted nanoparticles. J Magn Reson Imaging 2007; 25: 667680.
38.
Neubauer AM, Winter P, Caruthers S, Lanza GM, Wickline SA: Magnetic resonance
molecular imaging and targeted therapeutics. In: Contemporary Cardiology: Cardiovascular
magnetic resonance imaging. Kwong RY, ed. Humana Press; 2007; 639-662.
39.
Cyrus T, Lanza GM, Wickline SA: Molecular Imaging by Cardiovascular MR. J Cardiovasc
Magn Reson 2007; 9: 827-843.
40.
Lanza GM, Winter PM, Neubauer AM, Crowder KC, Caruthers SD, Wickline SA:
Atherosclerosis imaging with nanoparticles. In: Cardiovascular Molecular Imaging. Sinusas
and Groppler (In press)
41.
Lanza GM, Winter PM, Caruthers SD, Cyrus T, Yu X, Abendschein DR, Werkmeister J,
Ramshaw J, Wickline SA. Targeted drug delivery with novel paramagnetic nanoparticles:
Implications for MR interventional cardiology. Cardiovascular Reviews and Reports (In press)
34
35